Stroke – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Stroke - Pipeline Review, H1 2012', provides an overview of the Stroke therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. 'Stroke - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Stroke.
- A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Stroke pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Stroke.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Stroke therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Stroke Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Stroke 13
Stroke Therapeutics under Development by Companies 15
Stroke Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Comparative Analysis 26
Early Clinical Stage Products 27
Comparative Analysis 27
Discovery and Pre-Clinical Stage Products 28
Comparative Analysis 28
Stroke Therapeutics – Products under Development by Companies 29
Stroke Therapeutics – Products under Investigation by Universities/Institutes 35
Companies Involved in Stroke Therapeutics Development 39
Bristol-Myers Squibb Company 39
Johnson & Johnson 40
F. Hoffmann-La Roche Ltd. 41
NsGene A/S 42
Sanofi-Aventis 43
Athersys, Inc. 44
GlaxoSmithKline plc 45
Daiichi Sankyo Company, Ltd 46
CardioVascular BioTherapeutics, Inc. 47
Aldagen, Inc. 48
Henry Ford Health System 49
Novartis AG 50
Glenmark Pharmaceuticals Ltd. 51
H Lundbeck A/S 52
Mitsubishi Tanabe Pharma Corporation 53
Pfizer Inc. 54
Talecris Biotherapeutics Holdings Corp 55
Celgene Corporation 56
Bayer AG 57
Vernalis plc 58
Anavex Life Sciences Corp. 59
Neuralstem, Inc. 60
Living Cell Technologies Limited 61
Advanced Life Sciences Holdings, Inc. 62
Portola Pharmaceuticals, Inc. 63
RegeneRx Biopharmaceuticals, Inc. 64
Unigene Laboratories, Inc. 65
POZEN Inc. 66
ReNeuron Group plc 67
BioInvent International AB 68
SYGNIS Pharma AG 69
Torrent Pharmaceuticals Limited 70
Dongwha Pharm Co., Ltd. 71
Pluristem Therapeutics Inc. 72
ThromboGenics NV 73
NeuroVive Pharmaceutical AB 74
InDex Pharmaceuticals AB 75
D-Pharm Ltd. 76
StemCells, Inc. 77
Maywufa Company Limited 78
KeyNeurotek Pharmaceuticals AG 79
BioMAS Ltd. 80
Artielle ImmunoTherapeutics, Inc. 81
Regado Biosciences. 82
Fina Biotech 83
Angion Biomedica Corp. 84
Omeros Corporation 85
Cornerstone Therapeutics Inc. 86
Palkion, Inc. 87
Stemedica Cell Technologies, Inc. 88
Taligen Therapeutics Inc. 89
SanBio, Inc. 90
KAI Pharmaceuticals Inc. 91
Lacer, S.A. 92
M's Science Corporation 93
Thrombotech Technologies, Ltd. 94
ArmaGen Technologies, Inc. 95
Sinapis Pharma, Inc 96
RNL BIO Co., Ltd. 97
Cellmid Ltd 98
InVasc Therapeutics, Inc. 99
PHARMENA SA 100
Artery Therapeutics, Inc. 101
Stempeutics Research Private Limited 102
Stroke – Therapeutics Assessment 103
Assessment by Monotherapy Products 103
Assessment by Combination Products 104
Assessment by Route of Administration 105
Assessment by Molecule Type 107
Drug Profiles 110
Desmoteplase - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Eliquis - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Xarelto - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
DP-b99 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
PA32540 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Amantadine - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Aspirin + Cilostazol - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Aspirin - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Aricept - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Polypill - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 125
Effient - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Clopidogrel + Aspirin - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Recombinant Tissue Plasminogen Activator - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Human Serum Albumin - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Candesartan Cilexetil - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Clopidogrel - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Lithium Carbonate - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Magnesium Sulfate - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Glyceryl Trinitrate - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Xiaoshuanchangrong - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Dapsone - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
Propranolol - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Insulin - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Angongniuhuang - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Aricept - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Noscapine - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Rosuvastatin - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
Low-Dose Recombinant Tissue Plasminogen Activator - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
Activase - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
Stroke Therapeutics – Drug Profile Updates 150
Stroke Therapeutics – Discontinued Products 159
Stroke Therapeutics - Dormant Products 163
Stroke – Product Development Milestones 168
Featured News & Press Releases 168
Jan 11, 2012: New Data Demonstrate Stability Of ReNeuron’s Lead Stem Cell Line In Scale-up Conditions 168
Jan 06, 2012: NICE Asks For More Information On Bayers's Rivaroxaban 168
Jan 03, 2012: ReNeuron Announces Positive Data From Pivotal Preclinical Study Of ReN001 Stem Cell Line For Stroke 169
Dec 22, 2011: Bayer Submits Marketing Authorization Application To EMA For Xarelto 170
Dec 15, 2011: SYGNIS Announces Key Results Of Phase II Trial Of AX200 In Acute Ischemic Stroke 171
Dec 07, 2011: FDA Conducts Safety Review For Boehringer Ingelheim's Pradaxa 171
Nov 28, 2011: ReNeuron Provides Update On Phase I Clinical Trial Of ReN001 Stem Cell Therapy 172
Nov 23, 2011: Boehringer's Pradaxa Receives Prix Galien Award In Canada 173
Nov 18, 2011: European Medicines Agency Reports On Safety Of Pradaxa 174
Nov 16, 2011: New Analysis Of Data Presented At AHA Shows Effects Of Effient On Cardiovascular Events In STEMI Patients 174
Appendix 177
Methodology 177
Coverage 177
Secondary Research 177
Primary Research 177
Expert Panel Validation 178
Contact Us 178
Disclaimer 178
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Stroke, H1 2012 13
Products under Development for Stroke – Comparative Analysis, H1 2012 14
Number of Products under Development by Companies, H1 2012 16
Number of Products under Development by Companies, H1 2012 (Contd..1) 17
Number of Products under Development by Companies, H1 2012 (Contd..2) 18
Number of Products under Development by Companies, H1 2012 (Contd..3) 19
Number of Products under Development by Companies, H1 2012 (Contd..4) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 24
Comparative Analysis by Late Stage Development, H1 2012 25
Comparative Analysis by Mid Clinical Stage Development, H1 2012 26
Comparative Analysis by Early Clinical Stage Development, H1 2012 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 28
Products under Development by Companies, H1 2012 29
Products under Development by Companies, H1 2012 (Contd..1) 30
Products under Development by Companies, H1 2012 (Contd..2) 31
Products under Development by Companies, H1 2012 (Contd..3) 32
Products under Development by Companies, H1 2012 (Contd..4) 33
Products under Development by Companies, H1 2012 (Contd..5) 34
Products under Investigation by Universities/Institutes, H1 2012 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 38
Bristol-Myers Squibb Company, H1 2012 39
Johnson & Johnson, H1 2012 40
F. Hoffmann-La Roche Ltd., H1 2012 41
NsGene A/S, H1 2012 42
Sanofi-Aventis, H1 2012 43
Athersys, Inc., H1 2012 44
GlaxoSmithKline plc, H1 2012 45
Daiichi Sankyo Company, Ltd, H1 2012 46
CardioVascular BioTherapeutics, Inc., H1 2012 47
Aldagen, Inc., H1 2012 48
Henry Ford Health System, H1 2012 49
Novartis AG, H1 2012 50
Glenmark Pharmaceuticals Ltd., H1 2012 51
H Lundbeck A/S, H1 2012 52
Mitsubishi Tanabe Pharma Corporation, H1 2012 53
Pfizer Inc., H1 2012 54
Talecris Biotherapeutics Holdings Corp, H1 2012 55
Celgene Corporation, H1 2012 56
Bayer AG, H1 2012 57
Vernalis plc, H1 2012 58
Anavex Life Sciences Corp., H1 2012 59
Neuralstem, Inc., H1 2012 60
Living Cell Technologies Limited, H1 2012 61
Advanced Life Sciences Holdings, Inc., H1 2012 62
Portola Pharmaceuticals, Inc., H1 2012 63
RegeneRx Biopharmaceuticals, Inc., H1 2012 64
Unigene Laboratories, Inc., H1 2012 65
POZEN Inc., H1 2012 66
ReNeuron Group plc, H1 2012 67
BioInvent International AB, H1 2012 68
SYGNIS Pharma AG, H1 2012 69
Torrent Pharmaceuticals Limited, H1 2012 70
Dongwha Pharm Co., Ltd., H1 2012 71
Pluristem Therapeutics Inc., H1 2012 72
ThromboGenics NV, H1 2012 73
NeuroVive Pharmaceutical AB, H1 2012 74
InDex Pharmaceuticals AB, H1 2012 75
D-Pharm Ltd., H1 2012 76
StemCells, Inc., H1 2012 77
Maywufa Company Limited, H1 2012 78
KeyNeurotek Pharmaceuticals AG, H1 2012 79
BioMAS Ltd., H1 2012 80
Artielle ImmunoTherapeutics, Inc., H1 2012 81
Regado Biosciences., H1 2012 82
Fina Biotech, H1 2012 83
Angion Biomedica Corp., H1 2012 84
Omeros Corporation, H1 2012 85
Cornerstone Therapeutics Inc., H1 2012 86
Palkion, Inc., H1 2012 87
Stemedica Cell Technologies, Inc., H1 2012 88
Taligen Therapeutics Inc., H1 2012 89
SanBio, Inc., H1 2012 90
KAI Pharmaceuticals Inc., H1 2012 91
Lacer, S.A., H1 2012 92
M's Science Corporation, H1 2012 93
Thrombotech Technologies, Ltd., H1 2012 94
ArmaGen Technologies, Inc., H1 2012 95
Sinapis Pharma, Inc, H1 2012 96
RNL BIO Co., Ltd., H1 2012 97
Cellmid Ltd, H1 2012 98
InVasc Therapeutics, Inc., H1 2012 99
PHARMENA SA, H1 2012 100
Artery Therapeutics, Inc., H1 2012 101
Stempeutics Research Private Limited, H1 2012 102
Assessment by Monotherapy Products, H1 2012 103
Assessment by Combination Products, H1 2012 104
Assessment by Stage and Route of Administration, H1 2012 106
Assessment by Molecule Type, H1 2012 109
Stroke Therapeutics – Drug Profile Updates 150
Stroke Therapeutics – Discontinued Products 159
Stroke Therapeutics – Discontinued Products (Contd..1) 160
Stroke Therapeutics – Discontinued Products (Contd..2) 161
Stroke Therapeutics – Discontinued Products (Contd..3) 162
Stroke Therapeutics – Dormant Products 163
Stroke Therapeutics – Dormant Products (Contd..1) 164
Stroke Therapeutics – Dormant Products (Contd..2) 165
Stroke Therapeutics – Dormant Products (Contd..3) 166
Stroke Therapeutics – Dormant Products (Contd..4) 167
List of Figures
Number of Products under Development for Stroke, H1 2012 13
Products under Development for Stroke – Comparative Analysis, H1 2012 14
Products under Development by Companies, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 21
Late Stage Products, H1 2012 25
Mid Clinical Stage Products, H1 2012 26
Early Clinical Stage Products, H1 2012 27
Discovery and Pre-Clinical Stage Products, H1 2012 28
Assessment by Monotherapy Products, H1 2012 103
Assessment by Combination Products, H1 2012 104
Assessment by Route of Administration, H1 2012 105
Assessment by Stage and Route of Administration, H1 2012 106
Assessment by Molecule Type, H1 2012 107
Assessment by Stage and Molecule Type, H1 2012 108
[Tabellenverzeichnis ausblenden]